US Stock MarketDetailed Quotes

EVOK Evoke Pharma

Watchlist
  • 2.200
  • -0.045-2.02%
Close Apr 11 16:00 ET
  • 2.200
  • 0.0000.00%
Post 16:10 ET
3.28MMarket Cap-0.78P/E (TTM)

Evoke Pharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-9.50%-5.46M
-12.11%-1.24M
21.40%-818.7K
31.98%-820.62K
-58.16%-2.58M
24.42%-4.98M
55.87%-1.11M
5.39%-1.04M
12.18%-1.21M
-0.98%-1.63M
Net income from continuing operations
31.31%-5.35M
39.98%-1.19M
22.52%-1.31M
32.16%-1.27M
29.57%-1.58M
5.25%-7.79M
-10.21%-1.99M
15.89%-1.69M
16.36%-1.87M
-3.19%-2.24M
Other non cash items
-17.73%518.05K
1.92%142.71K
-23.85%126.03K
-23.62%124.66K
-22.56%124.66K
1,600.75%629.7K
469.28%140.03K
--165.5K
--163.21K
--160.96K
Change In working capital
-233.18%-1.4M
-198.10%-450.92K
15.14%236.08K
-10.46%195.37K
-927.09%-1.38M
692.62%1.05M
142.45%459.63K
-62.36%205.04K
-55.72%218.19K
-6.16%166.64K
-Change in receivables
-3,522.18%-1.75M
-170.94%-397.86K
90.71%-19.52K
-63.77%-551.1K
-1,146.73%-778.83K
85.37%-48.24K
1,018.58%560.83K
32.08%-210.09K
-731.74%-336.51K
49.51%-62.47K
-Change in inventory
117.06%32.84K
92.36%44.41K
484.47%51.36K
129.57%44.01K
-41.66%-106.94K
-85.34%-192.46K
--23.09K
--8.79K
---148.85K
---75.49K
-Change in prepaid assets
-6.67%29.8K
9.66%-719.64K
-7.88%227.49K
-0.04%299.92K
-21.14%222.05K
209.33%31.93K
13.24%-796.62K
-28.11%246.95K
-5.75%300.04K
23.98%281.57K
-Change in payables and accrued expense
-78.86%293.39K
-8.41%628.63K
-111.69%-23.25K
-8.94%402.54K
-1,277.04%-714.53K
119.57%1.39M
896.33%686.34K
-61.97%198.87K
264.96%442.07K
-18.18%60.71K
-Change in other current liabilities
95.02%-6.46K
53.88%-6.46K
--0
--0
--0
-250.31%-129.7K
43.08%-14K
-217.61%-39.47K
---38.56K
---37.68K
Cash from discontinued investing activities
Operating cash flow
-9.50%-5.46M
-12.11%-1.24M
21.40%-818.7K
31.98%-820.62K
-58.16%-2.58M
24.42%-4.98M
55.87%-1.11M
5.39%-1.04M
12.18%-1.21M
-0.98%-1.63M
Investing cash flow
Cash flow from continuing investing activities
Cash from discontinued investing activities
Financing cash flow
Cash flow from continuing financing activities
12,100.33%14.32M
3,031.88%3.5M
2.98M
295.7K
7.54M
-101.64%-119.3K
-119.3K
0
0
0
Net common stock issuance
--6.72M
--0
---191
---1
--6.72M
--0
--0
--0
--0
--0
Proceeds from stock option exercised by employees
--8.02M
--3.48M
--3M
--295.7K
--1.25M
--0
--0
--0
--0
--0
Net other financing activities
-257.34%-426.29K
--15.5K
---15.5K
--0
---426.29K
19.93%-119.3K
----
----
----
----
Cash from discontinued financing activities
Financing cash flow
12,100.33%14.32M
3,031.88%3.5M
--2.98M
--295.7K
--7.54M
-101.64%-119.3K
---119.3K
--0
--0
--0
Net cash flow
Beginning cash position
-51.85%4.74M
90.10%11.34M
30.99%9.18M
18.14%9.7M
-51.85%4.74M
7.64%9.84M
-51.70%5.96M
-47.91%7.01M
6.64%8.21M
7.64%9.84M
Current changes in cash
273.52%8.86M
284.23%2.26M
307.49%2.16M
56.49%-524.92K
404.33%4.96M
-830.24%-5.1M
51.11%-1.23M
5.39%-1.04M
-120.98%-1.21M
-12.98%-1.63M
End cash Position
186.88%13.6M
186.88%13.6M
90.10%11.34M
30.99%9.18M
18.14%9.7M
-51.85%4.74M
-51.85%4.74M
-51.70%5.96M
-47.91%7.01M
6.64%8.21M
Free cash flow
-9.50%-5.46M
-12.11%-1.24M
21.40%-818.7K
31.98%-820.62K
-58.16%-2.58M
24.42%-4.98M
55.87%-1.11M
5.39%-1.04M
12.18%-1.21M
-0.98%-1.63M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -9.50%-5.46M-12.11%-1.24M21.40%-818.7K31.98%-820.62K-58.16%-2.58M24.42%-4.98M55.87%-1.11M5.39%-1.04M12.18%-1.21M-0.98%-1.63M
Net income from continuing operations 31.31%-5.35M39.98%-1.19M22.52%-1.31M32.16%-1.27M29.57%-1.58M5.25%-7.79M-10.21%-1.99M15.89%-1.69M16.36%-1.87M-3.19%-2.24M
Other non cash items -17.73%518.05K1.92%142.71K-23.85%126.03K-23.62%124.66K-22.56%124.66K1,600.75%629.7K469.28%140.03K--165.5K--163.21K--160.96K
Change In working capital -233.18%-1.4M-198.10%-450.92K15.14%236.08K-10.46%195.37K-927.09%-1.38M692.62%1.05M142.45%459.63K-62.36%205.04K-55.72%218.19K-6.16%166.64K
-Change in receivables -3,522.18%-1.75M-170.94%-397.86K90.71%-19.52K-63.77%-551.1K-1,146.73%-778.83K85.37%-48.24K1,018.58%560.83K32.08%-210.09K-731.74%-336.51K49.51%-62.47K
-Change in inventory 117.06%32.84K92.36%44.41K484.47%51.36K129.57%44.01K-41.66%-106.94K-85.34%-192.46K--23.09K--8.79K---148.85K---75.49K
-Change in prepaid assets -6.67%29.8K9.66%-719.64K-7.88%227.49K-0.04%299.92K-21.14%222.05K209.33%31.93K13.24%-796.62K-28.11%246.95K-5.75%300.04K23.98%281.57K
-Change in payables and accrued expense -78.86%293.39K-8.41%628.63K-111.69%-23.25K-8.94%402.54K-1,277.04%-714.53K119.57%1.39M896.33%686.34K-61.97%198.87K264.96%442.07K-18.18%60.71K
-Change in other current liabilities 95.02%-6.46K53.88%-6.46K--0--0--0-250.31%-129.7K43.08%-14K-217.61%-39.47K---38.56K---37.68K
Cash from discontinued investing activities
Operating cash flow -9.50%-5.46M-12.11%-1.24M21.40%-818.7K31.98%-820.62K-58.16%-2.58M24.42%-4.98M55.87%-1.11M5.39%-1.04M12.18%-1.21M-0.98%-1.63M
Investing cash flow
Cash flow from continuing investing activities
Cash from discontinued investing activities
Financing cash flow
Cash flow from continuing financing activities 12,100.33%14.32M3,031.88%3.5M2.98M295.7K7.54M-101.64%-119.3K-119.3K000
Net common stock issuance --6.72M--0---191---1--6.72M--0--0--0--0--0
Proceeds from stock option exercised by employees --8.02M--3.48M--3M--295.7K--1.25M--0--0--0--0--0
Net other financing activities -257.34%-426.29K--15.5K---15.5K--0---426.29K19.93%-119.3K----------------
Cash from discontinued financing activities
Financing cash flow 12,100.33%14.32M3,031.88%3.5M--2.98M--295.7K--7.54M-101.64%-119.3K---119.3K--0--0--0
Net cash flow
Beginning cash position -51.85%4.74M90.10%11.34M30.99%9.18M18.14%9.7M-51.85%4.74M7.64%9.84M-51.70%5.96M-47.91%7.01M6.64%8.21M7.64%9.84M
Current changes in cash 273.52%8.86M284.23%2.26M307.49%2.16M56.49%-524.92K404.33%4.96M-830.24%-5.1M51.11%-1.23M5.39%-1.04M-120.98%-1.21M-12.98%-1.63M
End cash Position 186.88%13.6M186.88%13.6M90.10%11.34M30.99%9.18M18.14%9.7M-51.85%4.74M-51.85%4.74M-51.70%5.96M-47.91%7.01M6.64%8.21M
Free cash flow -9.50%-5.46M-12.11%-1.24M21.40%-818.7K31.98%-820.62K-58.16%-2.58M24.42%-4.98M55.87%-1.11M5.39%-1.04M12.18%-1.21M-0.98%-1.63M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion with Explanatory Notes--------

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

No. Symbol Price
Dorian LPG
LPG
20.540
Hutchmed (China)
HCM
13.720
Collegium Pharmaceutical
COLL
26.300
4
Halozyme Therapeutics
HALO
60.220
5
Precision Drilling
PDS
42.520
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Monetary Policy: Navigating the Fed's Rate Cut Cycle

Changing Fed policy is altering the market math for investors.